Drug Approval | April 26, 2022
DCGI grants Covaxin Emergency Use Approval for children 6-12 years
Covaxin was earlier approved for children 12-18 years of age
Covaxin was earlier approved for children 12-18 years of age
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
The launch is yet another first of its kind innovation in India
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Subscribe To Our Newsletter & Stay Updated
